COVID-19. Coronavirus infection, unspecified
Conditions
Interventions
Intervention 1: Intervention group: COVID-19 patients receiving hydroxychloroquine (200 mg every 12 hours), azithromycin (500 mg daily) and melatonin tablets (3 mg every night before bedtime) for up t
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Consent to attend the study Clinical symptoms Lymphocyte count less than 1100 Positive CT scan or C-reactive protein
Exclusion criteria
Exclusion criteria: Epilepsy Taking warfarin and other anticoagulants and coagulation disorders Uncontrolled diabetes and high blood pressure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stop the fever. Timepoint: It will be reviewed for 7 days from the study onset. Method of measurement: It is recorded by a thermometer.;Transfer to ICU. Timepoint: A maximum of 10 days of hospitalization will be checked. Method of measurement: Tracking hospitalized patients through questions and recording in questionnaires.;Mortality. Timepoint: A maximum of 10 days of hospitalization will be checked. Method of measurement: Tracking hospitalized patients through questions and recording in questionnaires.;Sleep quality. Timepoint: Days 1, 2, 3, and 7. Method of measurement: The Leeds Sleep Evaluation questionnaire will be used. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lymphopenia status. Timepoint: It will be reviewed on the first day and day 7. Method of measurement: Cell counter device.;C-reactive protein status. Timepoint: It will be reviewed on the first day and day 7. Method of measurement: Serology test.;Peripheral capillary oxygen saturation (SPO2). Timepoint: It will be reviewed on the first day and day 7. Method of measurement: Pulse Oximeter. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Abbas Mousavi
Mazandaran University of Medical Sciences
Outcome results
None listed